Human tuberculosis vaccine market

Tuberculosis (TB) is caused by a bacterium known as Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. There are two TB-related conditions which exist, they are latent TB infection (LTBI) and TB disease. Bacille Calmette-Guérin (BCG) is a vaccine for tuberculosis (TB) disease. This vaccine is not widely used in the U.S. However, it is often given to infants and small children in other countries  such as Nigeria, Norway, and Philippines where TB is common. BCG does not always protect people from getting TB. TB disease in children under 15 years of age (also called pediatric tuberculosis) is a public health problem of special significance because it is a marker of recent transmission of TB. For instance, according to data published by The Centers for Disease Control and Prevention In 2020, U.S. state, local, and territorial health agencies reported a total of 7,174 TB cases among children aged 14 years or younger in the U.S., accounting for 4% of all people reported with TB nationally.

Global human tuberculosis vaccine market is estimated to be valued at US$ 50.57 Mn in 2022 and is expected to exhibit a CAGR of 4.0% over the forecast period (2022-2030).

Figure 1: Global Human Tuberculosis Vaccine Market Share (%) Analysis, By Age Group, 2022

Increasing number of tuberculosis disease awareness campaigns conducted by government authorities is expected to drive the global human tuberculosis vaccine market growth over the forecast period.

Increasing number of tuberculosis disease awareness campaigns conducted by government authorities is expected to provide lucrative opportunities to market players in the global human tuberculosis vaccine market. For instance, on March 24, 2022, the Moroccan Ministry of Health and Social Protection launched its sixth national campaign to facilitate  the early diagnosis of tuberculosis (TB) and improve treatment for the infection. The campaign took place from March 25 to June 30 under the slogan “Towards a national mobilization to save lives and eliminate tuberculosis in Morocco”.

Increasing prevalence and incidence rate of tuberculosis is expected to drive global human tuberculosis vaccine market growth over the forecast period.

Increasing prevalence and incidence rate of tuberculosis is expected to drive the global human tuberculosis vaccine market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention in March 2022, the reported incidence of tuberculosis increased 9.4%, from 2.2 during 2020 to 2.4 during 2021 but was lower than incidence during 2019 (2.7). Increase occurred among both U.S.-born and non–U.S.-born persons. Moreover, according to the TBFacts.org in 2020, the estimated prevalence of TB (all ages, all forms) in South Africa in 2018 was 737 (95% CI 580-890) per 100,000 population.

Global Human Tuberculosis Vaccine Market- Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has hampered and disrupted the overall healthcare facilities all over the globe. For instance, according to a report published on April 21, 2022 by the New England Journal of Medicine, the World Health Organization (WHO) estimated that nearly 10 million people developed tuberculosis in 2020 and only 5.8 million cases were diagnosed and reported. However, it reflected an 18% decrease from 2019. This decrease was concentrated in 16 countries, with Asian countries (especially India, Indonesia, the Philippines, and China) seeing the largest reductions in case reporting. These countries all had major Covid-19 outbreaks and health care service disruptions.

Global Human Tuberculosis Vaccine Market– Restraints

The termination of clinical trials of tuberculosis vaccine is expected to hinder growth of the global human tuberculosis vaccine market. For instance, in August 2018, GlaxoSmithKline Plc., a pharmaceutical company, announced the termination of their clinical trial for tuberculosis (TB) vaccine candidate GSK 692342, due to a safety signal found at a planned interim safety review. Further conduct of this safety study was not recommended, and hence, the study was terminated. The trial was in Phase 2.

Global Human Tuberculosis Vaccine Market– Regional Analysis

On the basis of region, the global human tuberculosis vaccine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, Asia Pacific is expected to hold a dominant position in market during the forecast period, owing to, increasing research and development activities for tuberculosis vaccine in Asia Pacific region. For instance, in March 2022, the Indian Council of Medical Research (ICMR) started conducting Phase 3 double-blind placebo control trials across India. In Maharashtra, it has been conducted at two sites under ICMR-NARI (National AIDS Research Institute) Pune. At present, a total of 1,593 participants are randomized at Pune, India and their follow up for 38 months is ongoing. Efficacy and safety of two candidate TB vaccines will be studied under this trial. The two vaccines under study are VPM1002 and Immuvac.

Figure 2: Global Human Tuberculosis Vaccine Market Value (US$ Mn), by Region, 2022

Global Human Tuberculosis Vaccine Market– Competitive Landscape

Major players operating in the global human tuberculosis vaccine market include GlaxoSmithKline Plc, Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Valneva SE, Archivel Farma, BIOFABRI (Zendal), Japan BCG Laboratory, GreenSignal Bio Pharma Private Limited (GSBPL), AJ Vaccines A/S, Taj Pharma India Limited, and Biomed Lublin S.A.

Detailed Segmentation:

• Global Human Tuberculosis Vaccine Market, by Route of Administration :
  • Intradermal
  • Percutaneous
• Global Human Tuberculosis Vaccine Market, by Age Group :
  • Pediatrics
  • Adults
• Global Human Tuberculosis Vaccine Market, by Distribution Channel :
  • Public
  • Private
• Global Human Tuberculosis Vaccine Market, By Region:
  • North America
    • By Route of Administration:
      • Intradermal
      • Percutaneous
    • By Age Group:
      • Pediatrics
      • Adults
    • By Distribution Channel:
      • Public
      • Private
    • By Country:
      • U.S.
      • Canada
  • Latin America
    • By Route of Administration:
      • Intradermal
      • Percutaneous
    • By Age Group:
      • Pediatrics
      • Adults
    • By Distribution Channel:
      • Public
      • Private
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Route of Administration:
      • Intradermal
      • Percutaneous
    • By Age Group:
      • Pediatrics
      • Adults
    • By Distribution Channel:
      • Public
      • Private
    • By Country:
      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Route of Administration:
      • Intradermal
      • Percutaneous
    • By Age Group:
      • Pediatrics
      • Adults
    • By Distribution Channel:
      • Public
      • Private
    • By Country:
      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • By Route of Administration:
      • Intradermal
      • Percutaneous
    • By Age Group:
      • Pediatrics
      • Adults
    • By Distribution Channel:
      • Public
      • Private
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Route of Administration:
      • Intradermal
      • Percutaneous
    • By Age Group:
      • Pediatrics
      • Adults
    • By Distribution Channel:
      • Public
      • Private
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa